Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
- 19 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 19 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.